Csl Ltd has released a press release.
FY2017 Profit Upgrade
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from CSL
- AFSTYLA (rFVIII-Single Chain) European Commission Approval
- Positive Results from CSL112 Phase 2b Trial
- Afstyla CHMP Recommendation
- FDA Accepts BLA for Hereditary Angioedema Therapy
- 2016 FY Results Announcements and Analysts Briefing
Later from CSL
- Half Year Results Analysts Presentation
- Half Year Results Release
- CSL to Acquire Majority Stake in Chinese Plasma Fractionator
- FDA approves CSL Berhings HAEGARDA
- CSL Response to Patent Infringement Complaint
Follow CSL into a list and get an email when it puts out news.
Follow CSL